Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
Mhibik M, Gaglione EM, Eik D, Herrick J, Le J, Ahn IE, Chiu C, Wielgos-Bonvallet M, Hiemstra IH, Breij ECW, Chen J, Reilly EB, Epling-Burnette PK, Szafer-Glusman E, Sun C, Wiestner A.
Mhibik M, et al. Among authors: chen j.
Blood Adv. 2023 Aug 8;7(15):4089-4101. doi: 10.1182/bloodadvances.2022009517.
Blood Adv. 2023.
PMID: 37219524
Free PMC article.